We strive to extend survival in some of the most aggressive forms of cancer. Patient images reflect patient(s) health status when photographed.
Baar, Switzerland
Joined June 2013
- Tweets2.2K
- Following228
- Followers2.8K
- Likes1.1K
Novocure has received a Not Approvable Letter from the U.S. FDA in response to its Premarket Approval (PMA) application for its treatment for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. Read more: investor.novocure.com/news-r…
174
Novocure today reported financial results for the third quarter that ended September 30, 2026. Read more in our press release: investor.novocure.com/news-r…
1
144
Novocure announced its clinical trial agreement with Verastem Oncology to evaluate TTFields therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, in locally advanced pancreatic cancer: investor.novocure.com/news-r…
Novocure announced today that its treatment for adult patients diagnosed with unresectable locally advanced pancreatic cancer was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for concomitant use with gemcitabine and nab-paclitaxel: investor.novocure.com/news-r…
3
209
Novocure will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Read more in our press release: investor.novocure.com/news-r…
130
Novocure announced today that management will participate in two upcoming investor events. Read more in our press release: investor.novocure.com/news-r…
2
730
Novocure today reported financial results for the second quarter that ended June 30, 2026. Read more in our press release: investor.novocure.com/news-r…
254
Novocure will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Read more in our press release: investor.novocure.com/news-r…
287
Novocure announced today that its treatment has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. investor.novocure.com/news-r…
Novocure announced topline results today from the Phase 3 TRIDENT trial. Read more in our press release: investor.novocure.com/news-r…
1
1
322
Novocure today reported financial results for the first quarter that ended March 31, 2026. Read more in our press release: investor.novocure.com/news-r…
304
Novocure will report financial results for the first quarter 2026 on April 30, 2026. Read more in our press release: novocure.com/novocure-report…
309
Novocure announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy. Read more in our press release: novocure.com/novocure-announ…
Today Novocure announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its treatment for non-small cell lung cancer through the country’s National Health Insurance coverage.
Read more in our press release: novocure.com/novocure-announ…
5
361
Novocure today reported financial results for the quarter and full year ended December 31, 2025.
Read more in our press release: novocure.com/novocure-report…
318
We are thrilled to see the news of our Optune Pax approval featured on the Nasdaq tower this morning.
Read more about the approval in our latest press release: novocure.com/us-fda-approves…
Thank you to the team at Nasdaq!
Yesterday, the U.S. Food and Drug Administration (FDA) approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.
Read more in our press release: novocure.com/us-fda-approves…
The U.S. Food and Drug Administration (FDA) has approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.
novocure.com/us-fda-approves…
Novocure today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Read more in our press release. novocure.com/novocure-announ…
1
443
Novocure announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Read more in our press release: novocure.com/novocure-presen…
4
577